Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PODD Stock Forecast 2026-2027
$154.16
Current Price
$10.68B
Market Cap
Buy 20
Hold 3
Sell 1
Wall St Analyst Ratings
Distance to PODD Price Targets
+143.3%
To High Target of $375.00
+68.7%
To Median Target of $260.00
+13.5%
To Low Target of $175.00
PODD Price Momentum
-10.1%
1 Week Change
-21.7%
1 Month Change
-50.4%
1 Year Change
-45.8%
Year-to-Date Change
-56.6%
From 52W High of $354.88
+3.9%
From 52W Low of $148.31
📊 TOP ANALYST CALLS
Did PODD Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Insulet is one of their latest high-conviction picks.
Latest PODD Stock Price Targets & Analyst Predictions
Based on our analysis of 37 Wall Street analysts, PODD has a bullish consensus with a median price target of $260.00 (ranging from $175.00 to $375.00). The overall analyst rating is Strong Buy (8.8/10). Currently trading at $154.16, the median forecast implies a 68.7% upside. This outlook is supported by 20 Buy, 3 Hold, and 1 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PODD Analyst Ratings
20
Buy
3
Hold
1
Sell
PODD Price Target Range
Low
$175.00
Average
$260.00
High
$375.00
Current: $154.16
Latest PODD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PODD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 8, 2026 | Barclays | Matt Miksic | Underweight | Maintains | $198.00 |
| May 7, 2026 | Canaccord Genuity | William Plovanic | Buy | Maintains | $249.00 |
| May 7, 2026 | JP Morgan | Robbie Marcus | Overweight | Maintains | $275.00 |
| May 7, 2026 | Oppenheimer | Suraj Kalia | Outperform | Maintains | $210.00 |
| May 7, 2026 | Bernstein | Lee Hambright | Outperform | Maintains | $200.00 |
| May 7, 2026 | Wells Fargo | Lawrence Biegelsen | Overweight | Maintains | $255.00 |
| May 7, 2026 | Evercore ISI Group | Daniel Markowitz | Outperform | Maintains | $200.00 |
| May 7, 2026 | Truist Securities | Richard Newitter | Buy | Maintains | $250.00 |
| May 7, 2026 | RBC Capital | Shagun Singh | Outperform | Maintains | $280.00 |
| May 6, 2026 | BTIG | Marie Thibault | Buy | Maintains | $260.00 |
| Apr 24, 2026 | Rothschild & Co | Issie Kirby | Neutral | Downgrade | $220.00 |
| Apr 15, 2026 | Truist Securities | Richard Newitter | Buy | Maintains | $315.00 |
| Apr 9, 2026 | Goldman Sachs | David Roman | Buy | Maintains | $277.00 |
| Apr 7, 2026 | Citigroup | Joanne Wuensch | Neutral | Downgrade | $230.00 |
| Mar 11, 2026 | Citigroup | Joanne Wuensch | Buy | Maintains | $338.00 |
| Feb 19, 2026 | JP Morgan | Robbie Marcus | Overweight | Maintains | $340.00 |
| Feb 19, 2026 | Canaccord Genuity | William Plovanic | Buy | Maintains | $435.00 |
| Feb 19, 2026 | Truist Securities | Richard Newitter | Buy | Maintains | $360.00 |
| Feb 19, 2026 | Goldman Sachs | David Roman | Buy | Maintains | $326.00 |
| Feb 19, 2026 | Oppenheimer | Suraj Kalia | Outperform | Maintains | $300.00 |
Insulet Corporation (PODD) Competitors
The following stocks are similar to Insulet based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Insulet Corporation (PODD) Financial Data
Insulet Corporation has a market capitalization of $10.68B with a P/E ratio of 36.3x. The company generates $2.90B in trailing twelve-month revenue with a 10.4% profit margin.
Revenue growth is +33.9% quarter-over-quarter, while maintaining an operating margin of +16.0% and return on equity of +23.0%.
Valuation Metrics
Market Cap
$10.68B
Enterprise Value
$11.76B
P/E Ratio
36.3x
PEG Ratio
0.2x
Price/Sales
3.7x
Growth & Margins
Revenue Growth (YoY)
+33.9%
Gross Margin
+69.5%
Operating Margin
+16.0%
Net Margin
+10.4%
EPS Growth
+157.3%
Financial Health
Cash/Price Ratio
+4.5%
Current Ratio
2.5x
Debt/Equity
78.0x
ROE
+23.0%
ROA
+9.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Insulet Corporation (PODD) Business Model
About Insulet Corporation
What They Do
Develops innovative insulin delivery systems.
Business Model
The company primarily generates revenue by selling its Omnipod product platform, which includes the Omnipod 5 Automated Insulin Delivery system and the Omnipod DASH system. These devices enable insulin-dependent diabetes patients to manage their condition more effectively through tubeless, automated insulin delivery, which reduces the need for multiple daily injections.
Additional Information
Insulet Corporation operates in over 25 countries and has established partnerships to adapt its Pod technology for non-insulin drug delivery. Founded in 2000 and headquartered in Acton, Massachusetts, the company is recognized as a leader in tubeless automated insulin delivery solutions, aiming to enhance patient freedom and simplify diabetes management.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
5,400
CEO
Ms. Ashley A. McEvoy
Country
United States
IPO Year
2007
Website
www.insulet.comInsulet Corporation (PODD) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates
Evolus (EOLS) delivered earnings and revenue surprises of +25.93% and +0.59%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
May 04, 2026
By Zacks Equity Research
Tale of the Tape
Insulet (PODD) is an Incredible Growth Stock: 3 Reasons Why
Insulet (PODD) possesses solid growth attributes, which could help it handily outperform the market.
May 04, 2026
By Zacks Equity Research
Tale of the Tape
Insulet (PODD) Upgraded to Buy: Here's Why
Insulet (PODD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
May 04, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Insulet raised its annual revenue growth forecast following stronger-than-expected quarterly results, fueled by high demand for its tubeless insulin pumps.
Why It Matters
Insulet's raised revenue forecast signals strong future growth, driven by high demand for its innovative insulin pumps, potentially leading to increased investor confidence and stock performance.
Source: Reuters
Market Sentiment:
Positive
Insulin Pump-Maker Jumps On Beat And Raise
4 days ago
Quick Summary
Insulet's stock rose following a strong first-quarter report and an increased sales guidance for the year.
Why It Matters
Insulet's strong Q1 results and raised sales guidance indicate robust growth potential, likely leading to increased investor confidence and a positive stock trajectory.
Source: Investors Business Daily
Market Sentiment:
Positive
Quick Summary
Insulet Corporation (PODD) held its Q1 2026 earnings call, discussing financial performance and future expectations. Details from the call are crucial for investor insights.
Why It Matters
The earnings call reveals Insulet's financial performance and strategic direction, impacting stock valuation and investor confidence in its growth potential.
Source: Seeking Alpha
Market Sentiment:
Neutral
Insulet Reports First Quarter 2026 Results
4 days ago
Quick Summary
Insulet Corporation reported Q1 2026 revenue of $761.7 million, a 33.9% increase, surpassing guidance of 25%-27%. Omnipod revenue totaled $758.4 million.
Why It Matters
Insulet's strong Q1 revenue growth of 33.9%, surpassing guidance, indicates robust demand for its Omnipod products, signaling potential for continued market expansion and profitability.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Insulet (PODD) reported quarterly earnings of $1.42 per share, exceeding the Zacks Consensus Estimate of $1.14. This is an increase from $1.02 per share a year earlier.
Why It Matters
Insulet's earnings beat expectations and show year-over-year growth, indicating strong financial performance and potential for future stock appreciation.
Source: Zacks Investment Research
Market Sentiment:
Positive
Insulet (PODD) Loses 17.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
4 days ago
Quick Summary
Insulet (PODD) is currently considered oversold, suggesting reduced selling pressure. Wall Street analysts are raising earnings estimates, indicating a possible trend reversal.
Why It Matters
Insulet's oversold status and upgraded earnings estimates suggest a possible rebound, signaling a favorable buying opportunity for investors looking for turnaround stocks.
Source: Zacks Investment Research
Market Sentiment:
Negative
Frequently Asked Questions About PODD Stock
What is Insulet Corporation's (PODD) stock forecast for 2026?
Based on our analysis of 37 Wall Street analysts, Insulet Corporation (PODD) has a median price target of $260.00. The highest price target is $375.00 and the lowest is $175.00.
Is PODD stock a good investment in 2026?
According to current analyst ratings, PODD has 20 Buy ratings, 3 Hold ratings, and 1 Sell ratings. The stock is currently trading at $154.16. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PODD stock?
Wall Street analysts predict PODD stock could reach $260.00 in the next 12 months. This represents a 68.7% increase from the current price of $154.16. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Insulet Corporation's business model?
The company primarily generates revenue by selling its Omnipod product platform, which includes the Omnipod 5 Automated Insulin Delivery system and the Omnipod DASH system. These devices enable insulin-dependent diabetes patients to manage their condition more effectively through tubeless, automated insulin delivery, which reduces the need for multiple daily injections.
What is the highest forecasted price for PODD Insulet Corporation?
The highest price target for PODD is $375.00 from at , which represents a 143.3% increase from the current price of $154.16.
What is the lowest forecasted price for PODD Insulet Corporation?
The lowest price target for PODD is $175.00 from at , which represents a 13.5% increase from the current price of $154.16.
What is the overall PODD consensus from analysts for Insulet Corporation?
The overall analyst consensus for PODD is bullish. Out of 37 Wall Street analysts, 20 rate it as Buy, 3 as Hold, and 1 as Sell, with a median price target of $260.00.
How accurate are PODD stock price projections?
Stock price projections, including those for Insulet Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 10, 2026 10:38 PM UTC